Professor | 李淳朴 | 数字化转型顾问

Name

李淳朴

Contact Information

lichunpu@simm.ac.cn

Language ability

中文, 英语

Province

上海

University/Lab Affiliation and Title	中国科学院大学
Faculty	Medical School
Academic Background & Achievements	2010-09--2015-06 理学博士: 中国药科大学 2006-09--2010-06 理学学士: 中国药科大学
Work Experience	2022-11~现在 - 中国科学院上海药物研究所 - 研究员 2017-11~2022-10 - 中国科学院上海药物研究所 - 副研究员 2017-08~2017-10 - 中国科学院上海药物研究所 - 助理研究员 2015-07~2017-07 - 中国科学院上海药物研究所 - 博士后 2010-09~2015-06 - 中国药科大学 - 理学博士 2006-09~2010-06 - 中国药科大学 - 理学学士
Awards	赛诺菲-中国科学院上海生命科学研究院优秀青年人才奖励基金 (2020): 其他上海市科技进步奖 (2020): 一等奖, 省级上海市药学会药学科技奖 (2019): 一等奖, 省级创新人才推进计划重点领域创新团队 (2018): 部委级

University/Lab Affiliation and Title

中国科学院大学

Faculty

Medical School

Academic Background & Achievements

Work Experience

Awards

Areas of Focus	抗肿瘤药物
Publications	Discovery, Optimization, and Evaluation of Novel Pyridin-2(1H)-one Analogues as Potent TRK Inhibitors for Cancer Treatment, Journal of Medicinal Chemistry, 2024 Late-Stage Functionalization for the Divergent Synthesis of Podophyllotoxin Derivatives by Rhodium Catalysis, Chemistry - A European Journal, 2023 Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors, Journal of Medicinal Chemistry, 2023 盘状结构域受体1（DDR1）激酶抑制剂的研究进展, 有机化学, 2022 Structure-Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors, Journal of Medicinal Chemistry, 2022 Discovery of Pyrazolo3,4-dpyridazinone Derivatives as Selective DDR1 Inhibitors via Deep Learning Based Design, Synthesis, and Biological Evaluation, Journal of Medicinal Chemistry, 2022 Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma, Journal of Medicinal Chemistry, 2021 Design, synthesis and biological evaluation of pyrazolo3,4-dpyridazinone derivatives as covalent FGFR inhibitors, ACTA PHARMACEUTICA SINICA B, 2021 Discovery of 5-Benzylidene-2-phenyl-1,3-dioxane-4,6-diones as Highly Potent and Selective SIRT1 Inhibitors, ACS MEDICINAL CHEMISTRY LETTERS, 2021

Areas of Focus

抗肿瘤药物

Publications

Discovery, Optimization, and Evaluation of Novel Pyridin-2(1H)-one Analogues as Potent TRK Inhibitors for Cancer Treatment, Journal of Medicinal Chemistry, 2024
Late-Stage Functionalization for the Divergent Synthesis of Podophyllotoxin Derivatives by Rhodium Catalysis, Chemistry - A European Journal, 2023
Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors, Journal of Medicinal Chemistry, 2023
盘状结构域受体1（DDR1）激酶抑制剂的研究进展, 有机化学, 2022
Structure-Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors, Journal of Medicinal Chemistry, 2022
Discovery of Pyrazolo3,4-dpyridazinone Derivatives as Selective DDR1 Inhibitors via Deep Learning Based Design, Synthesis, and Biological Evaluation, Journal of Medicinal Chemistry, 2022
Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma, Journal of Medicinal Chemistry, 2021
Design, synthesis and biological evaluation of pyrazolo3,4-dpyridazinone derivatives as covalent FGFR inhibitors, ACTA PHARMACEUTICA SINICA B, 2021
Discovery of 5-Benzylidene-2-phenyl-1,3-dioxane-4,6-diones as Highly Potent and Selective SIRT1 Inhibitors, ACS MEDICINAL CHEMISTRY LETTERS, 2021

癌症化疗药物开发药理学肿瘤学分子生物学临床试验生物化学肿瘤抑制因子靶向治疗

任斌 - 武汉大学

Area of Focus
脊柱 | 骨骼 | 肿瘤 | 肿瘤学 | 手术 | 治疗 | 研究 | 临床试验 | 医疗保健 | 医学

黄勇 - 武汉大学

徐兵河 - 武汉大学

View All

Personal Information